A bitter pill to swallow: the need for better medications for drug-resistant tuberculosis in children

• Published in: The international journal of tuberculosis and lung disease 2015-12, Vol.19 (12), p.55
• Main Authors: Furin, J, Mafukidze, A, Brigden, G, du Cros, P, Golin, R, Harausz, E, Seddon, J A, Ustero, P, Garcia-Prats, A J
• Format: Article
• Language: English
• ISSN: 1815-7920

The large and growing access gap between the number of children who become sick with drug-resistant tuberculosis (DR-TB) and those who are treated for the disease each year represents a significant health systems failure. While there are multiple reasons why children with DR-TB are not diagnosed and treated, a serious challenge is the medications used to treat the disease. This paper presents three child DR-TB cases who were treated incorrectly; the cases are used to illustrate some of the problems with existing second-line medications. Challenges, including the perception that the drugs are more dangerous than the disease, lack of proper dosing recommendations and formulations, and the high cost of current treatment, all contribute to a perverse situation in which the most vulnerable pediatric patients are provided with a lower standard of care. This situation can be reversed with novel partnerships and training models, pharmacokinetic studies of the relevant drugs, increased collaboration, and dedicated funding, grounded in a rights-based approach to DR-TB in children.